Viridian Therapeutics, Inc.\DE·4

Feb 14, 4:05 PM ET

Tousignant Jennifer 4

4 · Viridian Therapeutics, Inc.\DE · Filed Feb 14, 2024

Insider Transaction Report

Form 4
Period: 2024-02-12
Tousignant Jennifer
Chief Legal Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2024-02-12+290,000290,000 total
    Exercise: $19.68Exp: 2034-02-12Common Stock (290,000 underlying)
Footnotes (1)
  • [F1]The option vests as to 25% on February 12, 2025 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4